Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-dose Methotrexate in Metastatic Breast Cancer with Leptomeningeal Metastasis
NCT02422641Phase 2Recruiting
- Sponsor
- Wake Forest University Health Sciences
- Start
- May 2015
- Primary completion
- Dec 2026
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of methotrexate in breast cancer, leptomeningeal metastasis (LM), sponsored by Wake Forest University Health Sciences. Started May 2015; status: recruiting.
02
Drugs
methotrexate
03
Conditions
breast cancerleptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT02422641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02422641.